Lucid Diagnostics (LUCD) Stock Statistics & Valuation Metrics

Lucid Diagnostics has a market cap or net worth of $101.62M. The enterprise value is $101.11M.

Lucid Diagnostics has 86.86M shares outstanding. The number of shares has decreased by -2.65% in one year.

Lucid Diagnostics’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -666.61%.

The current PE Ratio of Lucid Diagnostics is -0.91. Lucid Diagnostics’s PEG ratio is 0.02.

In the last 12 months, Lucid Diagnostics had revenue of $4.35M and earned -$45.53M in profits. Earnings per share was -$0.95.

In the last 12 months, operating cash flow was -$44.14M and capital expenditures -$646.00K, giving a free cash flow of -$44.79M billion.

Lucid Diagnostics pays an annual dividend of , resulting in a dividend yield of

Lucid Diagnostics upcoming earnings date is May 19, 2025, After Close.

Lucid Diagnostics as a current ratio of 1.07, with Debt / Equity ratio of 3.94

In the past 12 months, Lucid Diagnostics has paid $7.50B in taxes.

Lucid Diagnostics EV to EBITDA ratio is 0.02, with an EV/FCF ratio of 0.02.

Lucid Diagnostics has $22.36M in cash and marketable securities with $21.25M in debt, giving a net cash position of -$1.10M billion.

Gross margin is -63.35%, with operating margin of -1059.64%, and net profit margin of -1.05%.

The average price target for Lucid Diagnostics is $3.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy